-
China approves 4 new drugs, including a global first-in-class medicine
02 Jul 2025 21:48 GMT
… Medical Products Administration (NMPA) has approved four new drugs … ORR as second-line treatment, according to results … As China's biotech industry matures, the country … NMPA cleared Changchun GeneScience Pharmaceutical’s firsekibart (formerly genakumab …
-
Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review
09 May 2025 10:21 GMT
… of Drugs (2021 Trial Version)”, … including randomized controlled trials (RCTs), observational … drug indication in the treatment of CAPS, making it the first approved medication …
35. Novartis Pharmaceuticals Corporation EH, NJ. Ilaris [prescribing information …
-
Nocion Therapeutics Appoints Matthew Frankel, M.D., MBA to Chief Medical Officer
28 Apr 2025 12:14 GMT
… nociceptors for the treatment of serious conditions … refractory chronic cough trial forward to completion … for developing new drugs for oncology, immunology … Medical Unit, where he oversaw medical affairs and clinical development for Cosentyx®, Ilaris …
-
Key Trend Revolutionizing The Ilaris Market In 2025: Innovative Biologic Therapies For Treating Inflammatory Conditions
06 Mar 2025 23:13 GMT
… clinical trials and research activities
o Growing awareness of precision medicine
…
o Surge in medical tourism, enhancing treatment accessibility
Get Your … Food & Drug Administration (FDA) approval for Ilaris (canakinumab) as a treatment for gout …
-
October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
05 Mar 2025 21:57 GMT
… )
Drug reaction with eosinophilia and systemic symptoms
FDA is … FDA is evaluating the need for regulatory action.
Ilaris (canakinumab)
Kineret (anakinra)
Drug … reaction with eosinophilia and systemic symptoms
FDA …
-
Pharmacists Can Stay Aware of the Evolving Landscape of Gout Treatment to Address Unmet Needs
07 Feb 2025 19:03 GMT
… Takeda Pharmaceuticals) is used for gout treatment among … ) and canakinumab (Ilaris; Novartis Pharmaceuticals) are both IL … medications exactly as prescribed and check patients' records for possible drug-drug … 212 was granted FDA fast track designation …
-
Ilaris Global Market Report 2025: Insights, Trends and Projections Analyzed
27 Jan 2025 17:54 GMT
… amplified clinical trials, and growing awareness around precision medicine. Additionally, … pharmaceutical giant, announced the U.S. Food & Drug Administration approval for Ilaris … canakinumab as a treatment for …
-
7MM Gout Opportunity Assessment And Forecasts 2022-2024 & 2024-2032: Epidemiology, Current Treatment Options, Unmet Needs And Opportunities, Pipeline Assessment, R&D Strategies, Outlook
17 Jan 2025 11:53 GMT
… ULTs for chronic gout treatment. Significant growth is expected … under development for gout treatment. The most promising candidates … )
5.9. Product Profile: Ilaris (canakinumab)
6. Unmet Needs … Trials (Phase II/III) Overview
8.2. Trends in Clinical Trial …
-
Subcutaneous Biologics Market, Industry Trends And Global Forecasts To 2035: Subcutaneous Biologics Set To Transform Drug Delivery And Patient Adherence
16 Jan 2025 13:02 GMT
… traditional chemical-based medications, which are … offering targeted treatments with minimal drug interactions. Historically … (Amgen) STELARA (Janssen Biotech) Trulicity (Eli Lilly) … Alteogen Foresee Pharmaceuticals SUBCUTANEOUS FORMULATION TECHNOLOGIES …
-
FDA Grants Rare Pediatric Disease Designation to Small Molecule for Systemic Juvenile Idiopathic Arthritis
05 Dec 2024 18:19 GMT
… Treatments include corticosteroids as well as other immunosuppressive medications. Biologic medications … ; Sobi), canakinumab (Ilaris; Novartis), and tocilizumab … drugs and progress to stronger treatments … trials across 9 centers in India for the treatment …
About
© 1995-2025